Rajendra Apte, MD
Ophthalmology · Saint Louis, MONPI 1528062411
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $70,043 of the $112,070 with a category attached, or 62.5%. F. Hoffmann-la Roche AG accounts for 68.0% of it on its own, with 9 other manufacturers making up the rest. Among ophthalmology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 57 payments — averaging $1966.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$76K
- Genentech, Inc.$15K
- Merck$10K
- Novartis$5K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$4K
- Chugai Pharmaceutical Co., Ltd.$2K
- plus $273 from 4 others
Across 4 payments — averaging $7651.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$31K
What the payments were for
- Consulting fees$70,04362%
- Speaking & faculty fees$13,36912%
- Travel & lodging$26,88124%
- Food & beverage$1,7772%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 26 | $76,167 |
| Genentech, Inc. | 8 | $14,784 |
| Merck | 14 | $9,819 |
| Novartis | 2 | $4,673 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $4,000 |
| Chugai Pharmaceutical Co., Ltd. | 1 | $2,355 |
| Regeneron | 1 | $125 |
| Apellis Pharmaceuticals, Inc. | 1 | $121 |
| Biotissue Holdings Inc. | 2 | $19 |
| Maculogix, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$27,717
- Lucentis$8,215
- VABYSMO$6,547
- BEOVU$4,550
- STELLARIS PC$4,000
- EYLEA$125
- Syfovre$121
How this compares
$112,070 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Difluprednate | 15 | $1,881 |
| Prednisolone Acetate | 52 | $1,087 |
| Ketorolac Tromethamine | 37 | $491 |
| Timolol Maleate | 16 | $234 |
| Dorzolamide Hcl | 13 | $126 |
| Brimonidine Tartrate | 18 | $80 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 14 | $71 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Saint Louis
- Ranjan MalhotraSaint Louis$809K
- Gregg BerdySaint Louis$360K
- Ian PithaSaint Louis$85K
- Senthil KrishnasamySaint Louis$46K
- Navin TekwaniSaint Louis$34K
- Steven LeeSaint Louis$33K
- John GalanisSaint Louis$20K
- Bruce CohenSaint Louis$11K
- Waseem AnsariSaint Louis$9K
- Sean EdelsteinSaint Louis$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.